Panelists discuss how chronic kidney disease leads to iron deficiency anemia through a complex interplay of impaired iron absorption, increased hepcidin production driven by inflammatory cytokines, ...
PRINCETON, N.J., July 16, 2021 /PRNewswire/ — Sandoz, a global leader in generic and biosimilar medicines, today announced the immediate US availability of generic Ferumoxytol, an intravenous medicine ...
First and only high-dose intravenous iron for iron deficiency anemia of various etiologies SHIRLEY, N.Y.--(BUSINESS WIRE)--American Regent, Inc., a subsidiary of Luitpold Pharmaceuticals, Inc. (a ...
Monoferric will be supplied in 100mg/mL, 500mg/5mL, and 1000mg/10mL single-dose vials for intravenous infusion after dilution. The Food and Drug Administration (FDA) has approved Monoferric (ferric ...
(RTTNews) - Viatris (VTRS) announced the FDA has approved Iron Sucrose Injection, USP, an intravenous iron replacement product used to treat iron deficiency anemia in adult and pediatric patients with ...
DALLAS, Nov. 13, 2020 -- Patients who were hospitalized with acute heart failure and had iron deficiency were less likely to return to the hospital if given intravenous iron replacement, according to ...
Expands access to much-needed iron therapy for millions of US patients Builds Sandoz portfolio of high-quality injectable iron therapies and sets stage for future launches Strengthens US supply of ...
Please provide your email address to receive an email when new articles are posted on . The FDA approved the first and only IV iron replacement therapy indicated for people with heart failure and iron ...
Newspoint on MSN
Iron therapy explained: Who needs it and how it works
Iron therapy is a medical treatment used to correct severe iron deficiency when it cannot be managed through diet or regular ...
The Food and Drug Administration has given Viatris permission for iron sucrose injection, an intravenous iron replacement product used to treat iron deficiency anemia in adult and pediatric patients ...
Iron supplementation reduces heart failure (HF) readmissions in iron-deficient patients hospitalized for acute HF, according to results of the AFFIRM-AHF trial. After 52 weeks, intravenous ferric ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results